Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 18, 2018 07:30 ET | Source: Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer

WALTHAM, Mass., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
December 18, 2017 07:00 ET | Source: Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. Added to Russell 2000® Index

WALTHAM, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
November 28, 2017 07:00 ET | Source: Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors

WALTHAM, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
November 21, 2017 07:00 ET | Source: Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference

WALTHAM, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
November 20, 2017 07:00 ET | Source: Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

WALTHAM, Mass., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
November 14, 2017 07:00 ET | Source: Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights

-Presented Updated Clinical Data from Ongoing Phase 1 Trial of DCC-2618 at ESMO- -Completion of Initial Public Offering Raising Net Proceeds of $129 million- -Announced Plans to Initiate Two...
November 10, 2017 07:00 ET | Source: Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society

- Data Support the Selection of the Recommended Daily Dose of 150 mg - - Durable Disease Control Rates in Heavily Pretreated GIST Patients and Reductions in KIT Mutations Supporting pan-KIT Activity...
November 06, 2017 08:17 ET | Source: Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

WALTHAM, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
October 03, 2017 07:30 ET | Source: Deciphera Pharmaceuticals LLC

Deciphera Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares

WALTHAM, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
September 27, 2017 21:49 ET | Source: Deciphera Pharmaceuticals LLC

Deciphera Pharmaceuticals Announces Pricing of Initial Public Offering

WALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...